NCT03538743View on ClinicalTrials.gov

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

May 23, 2019

Study Completion Date

June 10, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Placebo

Tablet, 0 mg, twice daily, 28 days

DRUG

PF-06882961

Tablet, 15 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, 50 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, 150 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, 300 mg twice daily, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 5, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 6, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 7, 28 days

DRUG

PF-06882961

Tablet, dose TBD, twice daily, Cohort 8, 28 days

Trial Locations (4)

33143

Qps-Mra, Llc, South Miami

Qps-Mra,Llc, South Miami

66212

Altasciences Clinical Kansas, Inc., Overland Park

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03538743 - 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter